卡瑞利珠单抗治疗晚期高级别间叶源性肺恶性肿瘤1例并文献复习
Camrelizumab in the Treatment of Advanced High-Grade Mesenchymal Lung Malignancies: A Case Report and Literature Review
摘要: 目的：探讨晚期高级别间叶源性肺恶性肿瘤及相关疾病临床特点及诊治方法。方法：报道1例经穿刺活检病理提示高级别间叶源性肺恶性肿瘤患者临床资料，并复习相关文献。结果：经1周期化疗联合免疫治疗后，效果显著，后续由于副反应严重，行卡瑞利珠单抗单药治疗2年余，目前处于临床完全缓解状态。结论：晚期间叶源性肺恶性肿瘤及相关组织类型可从免疫治疗中获益。
Abstract: Objective: To investigate the clinical features, diagnosis and treatment of advanced high grade mesenchymal lung malignancies and related diseases. Methods: A retrospective analysis was per-formed for a patient with high-grade mesenchymal lung malignancy indicated by biopsy pathology and the relevant literature was reviewed. Results: After a cycle of chemotherapy combined with immunotherapy, the effect was significant. Due to serious side reactions, Camrelizumab was treated along for more than 2 years, and the patient was in complete response at present. Conclusion: Ad-vanced mesenchymal lung malignancies and related types can benefit from immunotherapy.
文章引用：周雨媛, 周非, 吕红英, 梁东海, 陈文秀, 于洪升. 卡瑞利珠单抗治疗晚期高级别间叶源性肺恶性肿瘤1例并文献复习[J]. 临床医学进展, 2023, 13(12): 19367-19374. https://doi.org/10.12677/ACM.2023.13122726

参考文献

[1] Lee, E. and Kazerooni, E.A. (2022) Lung Cancer Screening. Seminars in Respiratory and Critical Care Medicine, 43, 839-850. [Google Scholar] [CrossRef] [PubMed]
[2] Oliver, A.L. (2022) Lung Cancer: Epidemiology and Screening. Surgical Clinics of North America, 102, 335-344. [Google Scholar] [CrossRef] [PubMed]
[3] Giroux, D.J., Rami-Porta, R., Chansky, K., et al. (2009) The IASLC Lung Cancer Staging Project: Data Elements for the Prospective Project. Journal of Thoracic Oncology, 4, 679-683. [Google Scholar] [CrossRef] 
[4] Kotecha, R., Langer, C., Ernani, V., et al. (2022) First-Line Tumor Treating Fields (Ttfields; 150 KHZ) Therapy plus Pembrolizumab for Advanced or Metastatic Intrathoracic Non-Small Cell Lung Cancer: The Phase 2 EF-36/Keynote B36 Pilot Study. Journal for Immunotherapy of Cancer, 10, A735. [Google Scholar] [CrossRef] 
[5] Ettinger, D.S., Wood, D.E., Aisner, D.L., et al. (2022) Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 20, 497-530. [Google Scholar] [CrossRef] [PubMed]
[6] Ettinger, D.S., Wood, D.E., Aisner, D.L., et al. (2021) NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. Journal of the National Comprehensive Cancer Network, 19, 254-266. [Google Scholar] [CrossRef] [PubMed]
[7] Lococo, F., Torricelli, F., Rossi, G., et al. (2017) Inter-Relationship between PD-L1 Expression and Clinic-Pathological Features and Driver Gene Mutations in Pulmonary Sarcomatoid Car-cinomas. Lung Cancer, 113, 93-101. [Google Scholar] [CrossRef] [PubMed]
[8] Yadavilli, S., Waight, J.D., Brett, S., et al. (2023) Activating Inducible T-Cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Block-ade. Cancer Research Communications, 3, 1564-1579. [Google Scholar] [CrossRef] 
[9] Nishino, M., Ramaiya, N.H., Hatabu, H., et al. (2017) Monitoring Immune-Checkpoint Blockade: Response Evaluation and Biomarker Development. Nature Reviews Clinical Oncology, 14, 655-668. [Google Scholar] [CrossRef] [PubMed]
[10] Sobande, F., Samayoa, L.M., Moore, A.R., et al. (2011) Primary Pulmonary Synovial Sarcoma Presenting as a Breast Mass. The Breast Journal, 17, 418-419. [Google Scholar] [CrossRef] [PubMed]
[11] Janssen, J.P., Mulder, J.J., Wagenaar, S.S., et al. (1994) Primary Sarcoma of the Lung: A Clinical Study with Long-Term Follow-Up. The Annals of Thoracic Surgery, 58, 1151-1155. [Google Scholar] [CrossRef] [PubMed]
[12] Zheng, Y., Fu, Y., Zhong, Q., et al. (2022) The Treatment of Advanced Pulmonary Sarcomatoid Carcinoma. Future Oncology, 18, 727-738. [Google Scholar] [CrossRef] [PubMed]
[13] Weissferdt, A. (2018) Pulmonary Sarcomatoid Carcinomas: A Review. Advances in Anatomic Pathology, 25, 304-313. [Google Scholar] [CrossRef] 
[14] Gong, C., Xiong, H., Qin, K., et al. (2022) MET Alterations in Advanced Pulmonary Sarcomatoid Carcinoma. Frontiers in Oncology, 12, Article ID: 1017026. [Google Scholar] [CrossRef] [PubMed]
[15] Mok, T.S.K., Wu, Y.-L., Kudaba, I., et al. (2019) Pembrolizumab versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. The Lancet, 393, 1819-1830. [Google Scholar] [CrossRef] 
[16] Herbst, R.S., Baas, P., Kim, D.-W., et al. (2016) Pembroli-zumab versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial. The Lancet, 387, 1540-1550. [Google Scholar] [CrossRef] 
[17] Yang, J.-J., Huang, C., Fan, Y., et al. (2022) Camrelizumab in Different PD-L1 Expression Cohorts of Pre-Treated Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase II Study. Cancer Immunology, Immunotherapy, 71, 1393-1402. [Google Scholar] [CrossRef] [PubMed]
[18] Domblides, C., Leroy, K., Monnet, I., et al. (2020) Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma. Journal of Thoracic Oncology, 15, 860-866. [Google Scholar] [CrossRef] [PubMed]
[19] Zhou, C., Chen, G., Huang, Y., et al. (2021) Camrelizumab plus Carboplatin and Pemetrexed versus Chemotherapy Alone in Chemotherapy-Naive Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer (CameL): A Randomised, Open-Label, Multicentre, Phase 3 Trial. The Lancet Respiratory Medicine, 9, 305-314. [Google Scholar] [CrossRef] 
[20] Qian, X., Wang, Y., Liu, F., et al. (2022) The Efficacy and Safety Analysis of First-Line Immune Checkpoint Inhibitors in Pulmonary Sarcomatoid Carcinoma. Frontiers in Immu-nology, 13, Article ID: 956982. [Google Scholar] [CrossRef] [PubMed]

为你推荐